epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Fintepla
    fenfluramine
  • remove Kaopectate Soft Chews
    bismuth subsalicylate
  • remove Pepto-Bismol Ultra
    bismuth subsalicylate
  • remove Uptravi
    selexipag

multicheck MultiCheck Results - 3 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Kaopectate Soft Chews (bismuth subsalicylate) + Pepto-Bismol Ultra (bismuth subsalicylate)

Avoid/Use Alternative


bismuth subsalicylate + bismuth subsalicylate

avoid combo: combo may incr. risk of HTN, GI ulceration, perforation, bleeding, other adverse effects (additive effects, duplicate therapy)

Monitor/Modify Tx

Smiley face Smiley face Fintepla (fenfluramine) + Kaopectate Soft Chews (bismuth subsalicylate)

Monitor/Modify Tx


fenfluramine + bismuth subsalicylate

monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

Smiley face Smiley face Fintepla (fenfluramine) + Pepto-Bismol Ultra (bismuth subsalicylate)

Monitor/Modify Tx


fenfluramine + bismuth subsalicylate

monitor BP w/ high-dose bismuth subsalicylate: combo may incr. risk of HTN (additive effects)

Additional Considerations

Smiley face Smiley face fenfluramine in Fintepla

add MAO inhibitor to Interaction Check if recent (14 days) use

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information